Filing Analysis
SCYNEXIS, Inc. has implemented a 1-for-8 reverse stock split effective May 29, 2026, and reduced its authorized common stock from 150 million to 18.75 million shares. The split-adjusted stock is scheduled to begin trading on the Nasdaq Capital Market on June 1, 2026.
🚩 Red Flags
- Reverse stock splits in micro-cap companies are frequently used to artificially inflate share prices to avoid Nasdaq minimum bid price delisting requirements.
- Significant reduction in authorized share capital (from 150M to 18.75M) suggests a drastic contraction of the equity structure.
📋 Key Facts
- Reverse stock split ratio is 1-for-8 (1:8).
- Authorized shares reduced from 150,000,000 to 18,750,000.
- Effective date of the amendment was May 29, 2026.
- Nasdaq trading on a split-adjusted basis begins June 1, 2026.
- New CUSIP number is 811292 309.
- Fractional shares are paid out in cash; no fractional shares issued.
- Par value remains unchanged at $0.001 per share.
SCYNEXIS, Inc. (SCYX) held a special stockholder meeting on May 19, 2026, at which shareholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10. The Board subsequently selected a 1-for-8 ratio, effective May 29, 2026, with split-adjusted trading on Nasdaq commencing June 1, 2026. Authorized shares will be reduced from 150,000,000 to 18,750,000.
🚩 Red Flags
- Reverse stock split at a 1-for-8 ratio is a strong indicator of share price distress, typically executed to regain or maintain Nasdaq minimum bid price compliance ($1.00 minimum)
- Authorized share count reduction from 150,000,000 to 18,750,000 severely limits future capital raising flexibility via equity issuances
- Multiple 8-K items filed simultaneously (Items 5.07 and 8.01), compounding the significance of the event
- Pre-split share count of ~79.4 million shares for a micro-cap biotech implies significant prior dilution from equity offerings or compensation
- Cash payments for fractional shares may indicate a large number of small retail shareholders, adding minor administrative/liquidity complexity
📋 Key Facts
- Special Meeting held May 19, 2026; 51,638,303 of 79,442,633 eligible shares (65.0%) were present in person or by proxy
- Proposal 1 approved with 44,826,378 votes FOR, 6,708,960 AGAINST, and 102,965 abstentions (~86.8% of votes cast were in favor)
- Board approved a 1-for-8 reverse stock split on May 19, 2026; effective date is May 29, 2026
- Split-adjusted trading on Nasdaq Capital Market under ticker 'SCYX' commences June 1, 2026
- Every 8 shares of common stock will be automatically converted into 1 share
- Authorized shares of common stock reduced from 150,000,000 to 18,750,000; par value remains $0.001 per share
- New CUSIP number post-split: 811292 309
- Reverse split affects all outstanding shares, equity compensation plans, stock options, RSUs, and warrants; exercise prices will be adjusted proportionally
- No fractional shares will be issued; cash will be paid in lieu of fractional shares
- Filing signed by David Angulo, M.D., Chief Executive Officer, on May 22, 2026
Dr. Steven C. Gilman notified SCYNEXIS of his intent to retire from the Board of Directors and will not stand for reelection at the 2026 annual meeting. He currently serves as the Chair of the Compensation Committee and will remain in his roles until the conclusion of the upcoming annual meeting.
📋 Key Facts
- Dr. Steven C. Gilman notified the company of his retirement on April 16, 2026.
- Dr. Gilman will not stand for reelection at the 2026 Annual Meeting of stockholders.
- He currently serves as Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.
- The company stated there were no disagreements regarding operations, policies, or practices.
SCYNEXIS, Inc. furnished a corporate presentation and held a conference call on March 31, 2026, to discuss a previously announced asset acquisition transaction and provide a corporate update.
📋 Key Facts
- Conference call held on March 31, 2026, regarding an asset acquisition transaction.
- Corporate presentation dated March 2026 was furnished as Exhibit 99.1.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The report was signed by David Angulo, M.D., Chief Executive Officer.
SCYNEXIS entered into a $40 million private placement (PIPE) of common stock and warrants, with the potential for an additional $52.2 million in proceeds upon warrant exercise. The financing is expected to extend the company's cash runway into mid-2029 and includes participation from the CEO.
🚩 Red Flags
- Significant dilution: The offering involves up to 87 million shares/warrants, which is substantial for a micro-cap company.
- Authorized share constraint: The company requires stockholder approval to increase authorized shares, indicating they are likely near their current legal limit.
📋 Key Facts
- Agreed to issue 34,750,000 shares of common stock and 8,750,000 pre-funded warrants.
- Issued 43,500,000 common warrants with an exercise price of $1.20 per share.
- Combined purchase price was $0.92 per share/unit, representing approximately $40 million in initial gross proceeds.
- CEO Dr. David Angulo participated in the offering, purchasing 108,695 units.
- The company must convene a stockholder meeting within 90 days to approve an increase in authorized shares to accommodate the warrant exercises.
- Estimated cash runway extended into mid-2029 based on current plans and offering proceeds.
SCYNEXIS acquired Poxel SA's AMP kinase activator R&D program, including the lead compound PXL-770, for an upfront payment of $8 million and potential milestones totaling $188 million. The deal grants SCYNEXIS an exclusive, worldwide license to develop and commercialize the acquired assets.
🚩 Red Flags
- Significant contingent liabilities with up to $188 million in milestone obligations.
- Forward-looking statements explicitly mention the need to raise additional capital to fund the development and commercialization of these new assets.
📋 Key Facts
- One-time upfront payment of $8,000,000 due within 30 days of the March 30, 2026 agreement.
- Total potential milestone payments of $188,000,000, including $2,000,000 for Phase 2 initiation and $6,000,000 for Phase 3 initiation or U.S. approval.
- Commercial milestones include a $25,000,000 payment upon the first U.S. commercial sale.
- Sales-based milestones reach up to $75,000,000 for annual net sales exceeding $1.5 billion.
- Acquisition includes all patents, know-how, regulatory filings, and inventory related to the PXL-770 compound.